Investigation on the active ingredient and mechanism of Cannabis sativa L. for treating epilepsy based on network pharmacology

References

• Fiest K, Sauro K, Wiebe S, et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology. 2017;88(3):296–303.
   PubMed Web of Science ®Google Scholar
• Kissani N, Lengané YTM, Patterson V, et al. Telemedicine in epilepsy: how can we improve care, teaching, and awareness?Epilepsy Behav. 2020;103(Pt A):106854–106860.
   PubMedGoogle Scholar
• Devinsky O, Vezzani A, O’Brien TJ, et al. Epilepsy. Nat Rev Dis Primers. 2018;4(1):1–24.
   PubMedGoogle Scholar
• Prospéro-García O, Contreras AER, Gómez AO, Grupo de Neurociencias de la Universidad Nacional Autónoma de México, et al. Endocannabinoids as therapeutic targets. Arch Med Res. 2019;50(8):518–526.
   PubMed Web of Science ®Google Scholar
• Szaflarski JP, Bebin EM. Cannabis, cannabidiol, and epilepsy-from receptors to clinical response. Epilepsy Behav. 2014;41:277–282.
   PubMed Web of Science ®Google Scholar
• Wang Z, Liu J, Yu Y, et al. Modular pharmacology: the next paradigm in drug discovery. Expert Opin Drug Discov. 2012;7(8):667–677.
   PubMed Web of Science ®Google Scholar
• Wang Y, Yang L. Systems pharmacology based research framework of traditional Chinese medicine. World Chinese Med. 2013;8(7):103–110.
   Google Scholar
• Huang C, Zheng C, Li Y, et al. Systems pharmacology in drug discovery and therapeutic insight for herbal medicines. Brief Bioinform. 2014;15(5):710–733. doi:.
   PubMed Web of Science ®Google Scholar
• Ferreira LLG, Santos RN, Oliva G, et al. Molecular docking and structure-based drug design strategies. Molecules. 2015;20(7):13384–13421.
   PubMed Web of Science ®Google Scholar
• Hirayama N. Docking simulations between drugs and HLA molecules associated with idiosyncratic drug toxicity. Drug Metab Pharmacokinet. 2017;32(1):31–39.
   PubMed Web of Science ®Google Scholar
• Ru J, Li P, Jinan W, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminf. 2014;6(1):13–18.
   PubMed Web of Science ®Google Scholar
• Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7(1):42713–42717.
   PubMedGoogle Scholar
• Wang Y, Zhang S, Li F, et al. Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics. Nucleic Acids Res. 2020;48(D1):D1031–D1041.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1–10.
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504.
   PubMed Web of Science ®Google Scholar
• Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav. 2013;29(3):574–577.
   PubMed Web of Science ®Google Scholar
• Wallace M, Wiley JL, Martin BR, et al. Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. Eur J Pharmacol. 2001;428(1):51–57.
   PubMed Web of Science ®Google Scholar
• Urbanska M, Kazmierska-Grebowska P, Kowalczyk T, et al. GSK3β activity alleviates epileptogenesis and limits GluA1 phosphorylation. EBioMed. 2019;39:377–387.
   PubMed Web of Science ®Google Scholar
• Gorman KM, Meyer E, Grozeva D, NIHR BioResource, et al. Bi-allelic loss-of-function CACNA1B mutations in progressive epilepsy-dyskinesia. Am J Hum Genet. 2019;104(5):948–956.
   PubMed Web of Science ®Google Scholar
• Bozarth X, Dines JN, Cong Q, et al. Expanding clinical phenotype in CACNA1C related disorders: From neonatal onset severe epileptic encephalopathy to late-onset epilepsy. Am J Med Genet A. 2018;176(12):2733–2739.
   PubMed Web of Science ®Google Scholar
• Chemin J, Siquier-Pernet K, Nicouleau M, et al. De novo mutation screening in childhood-onset cerebellar atrophy identifies gain-of-function mutations in the CACNA1G calcium channel gene. Brain. 2018;141(7):1916–1998.
   Google Scholar
• Anjum R, Blenis J. The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol. 2008;9(10):747–758.
   PubMed Web of Science ®Google Scholar
• Kim EK, Choi E-J. Pathological roles of MAPK signalling pathways in human diseases. Biochim Biophys Acta. 2010;1802(4):396–405.
   PubMed Web of Science ®Google Scholar
• Kim S-W, Yu Y-M, Piao CS, et al. Inhibition of delayed induction of p38 mitogen-activated protein kinase attenuates kainic acid-induced neuronal loss in the hippocampus. Brain Res. 2004;1007(1-2):188–191.
   PubMed Web of Science ®Google Scholar
• Hernandez CC, Xiangwei W, Hu N, et al. Altered inhibitory synapses in de novo GABRA5 and GABRA1 mutations associated with early onset epileptic encephalopathies. Brain. 2019;142(7):1938–1954.
   PubMedGoogle Scholar
• Li R, Wu B, He M, et al. HAP1 modulates epileptic seizures by regulating GABAAR function in patients with temporal lobe epilepsy and in the PTZ-Induced epileptic model. Neurochem Res. 2020;45(9):1997–2008.
   PubMed Web of Science ®Google Scholar
• Treiman DM. GABAergic mechanisms in epilepsy. Epilepsia. 2001;42(s3):8–12.
   PubMed Web of Science ®Google Scholar
• Rumping L, Tessadori F, Pouwels PJ, et al. GLS hyperactivity causes glutamate excess, infantile cataract and profound developmental delay. Hum Mol Genet. 2019;28(1):96–104. doi:.
   PubMed Web of Science ®Google Scholar
• O’Shea RD. Roles and regulation of glutamate transporters in the central nervous system. Clin Exp Pharmacol Physiol. 2002;29(11):1018–1023.
   PubMed Web of Science ®Google Scholar
• Aragón C, López-Corcuera B. Structure, function and regulation of glycine neurotransporters. Eur J Pharmacol. 2003;479(1–3):249–262.
   PubMed Web of Science ®Google Scholar
• Rezaei M, Sadeghian A, Roohi N, et al. Epilepsy and dopaminergic system. Physiol Pharmacol. 2017;21(1):1–14.
   Web of Science ®Google Scholar
• Starr MS. The role of dopamine in epilepsy. Synapse. 1996;22(2):159–194.
   PubMed Web of Science ®Google Scholar
• Friedman A, Behrens CJ, Heinemann U. Cholinergic dysfunction in temporal lobe epilepsy. Epilepsia. 2007;48(s5):126–130.
   PubMedGoogle Scholar
• Lippert T, Gelineau L, Napoli E, et al. Harnessing neural stem cells for treating psychiatric symptoms associated with fetal alcohol spectrum disorder and epilepsy. Prog Neuro-Psychopharmacol Biol Psych. 2018;80(5):10–264.
   PubMedGoogle Scholar
• Gholami M, Saboory E, Ahmadi AA, et al. Long-time effects of prenatal morphine, tramadol, methadone, and buprenorphine exposure on seizure and anxiety in immature rats. Int J Neurosci. 2019;130(9):1–16.
   PubMed Web of Science ®Google Scholar
• Sugaya Y, Kano M. Control of excessive neural circuit excitability and prevention of epileptic seizures by endocannabinoid signalling. Cell Mol Life Sci. 2018;75(15):2793–2811.
   PubMed Web of Science ®Google Scholar